Research sheds new light on mechanisms of T-ALL, a form of leukemia that primarily affects children

Dec. 23, 2012 ? Acute lymphatic leukemia (ALL) is the most common cancer in children under the age of 14 years. With optimum treatment, approximately 75 percent of children are currently cured, but the treatment consists of severe chemotherapy with many side effects. In collaboration with international research teams, scientists at VIB, KU Leuven and UZ Leuven have identified new genetic mutations that lead to T-ALL, a variant of ALL. They have unmasked the ribosome -- the molecular machine in the cell that is involved in the production of proteins -- as a weak spot in leukemia cells.

Their research has also shown that there is a difference in T-ALL between adults and children. Both findings can be important in the search for improved treatments for T-ALL.

Jan Cools (VIB/KU Leuven): "We have discovered that there is a clear genetic difference between T-ALL in children and in adults. This could be an explanation why adults do not respond as well to the current therapy."

Stein Aerts (KU Leuven): "This is a beautiful example of the power of genome sequencing in cancer research. New technologies and large-scale bio-informatics allow us to study a lot of data simultaneously. This allows us to discover links that would have been impossible to find in the past."

T-cell acute lymphatic leukemia (T-ALL)

The formation of white blood cells is disrupted by leukemia. The cells in the bone marrow that should mature into white blood cells multiply unchecked without maturing completely. These immature blood cells compromise the production of normal blood cells. This makes patients more susceptible to infections. Leukemia occurs in different forms; in the case of T-ALL, there is an accumulation of immature white blood cells over a very short period of time. With optimum treatment -- involving chemotherapy -- approximately 75 % of children are currently cured. For adults, the chance of a cure is below 50 %. Chemotherapy is associated with many side effects. The search for a more specific treatment can only start once we know what causes T-ALL.

7 new genes with a key role in T-ALL identified

T-ALL only occurs if errors in various genes occur simultaneously. It is important to determine which genes play a key role. Kim De Keersmaecker, Zeynep Kalender Atak, Jan Cools and Stein Aerts have identified a series of defects in 15 important genes, of which 7 have not previously been associated with T-ALL. They used next-generation sequencing to analyze the 20,000+ genes of 67 T-ALL patients. This technique allows for very fast analysis and comparison of the complete DNA sequence of healthy and sick individuals.

A difference between adults and children

The investigators from Leuven also discovered a difference between T-ALL in children and in adults. T-ALL in adults contains significantly more mutations than in children. The leukemia cells in adults also contain mutations in other genes than in children. This genetic difference could be a possible explanation why adults do not respond as well to the current therapy.

A weak point in leukemia cells exposed

RPL5 and RPL10 -- two newly identified genes -- form part of the ribosome: this is the complex in the cell that produces proteins. The scientists hereby demonstrated for the first time that defects in the ribosome can also play a role in cancer activation. Experiments in yeast cells confirm that mutations in RPL10 cause a change in the ribosome.

Kim De Keersmaecker (VIB/KU Leuven): "This could be a weak point of the leukemia cells: all cells need properly functioning ribosomes to survive and to grow. These 'defective' ribosomes in the leukemia cells could be a new suitable target for the development of targeted therapies."

Patient information

As this study may raise many questions in patients, we would like to refer you to the e-mail address that the VIB has set up for this purpose. Anyone with questions about this research and other medical research can submit their questions on patients@vib.be. Please submit your question in Dutch or English only.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by VIB, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. Kim De Keersmaecker, Zeynep Kalender Atak, Ning Li, Carmen Vicente, Stephanie Patchett, Tiziana Girardi, Valentina Gianfelici, Ellen Geerdens, Emmanuelle Clappier, Micha?l Porcu, Idoya Lahortiga, Rossella Luc?, Jiekun Yan, Gert Hulselmans, Hilde Vranckx, Roel Vandepoel, Bram Sweron, Kris Jacobs, Nicole Mentens, Iwona Wlodarska, Barbara Cauwelier, Jacqueline Cloos, Jean Soulier, Anne Uyttebroeck, Claudia Bagni, Bassem A Hassan, Peter Vandenberghe, Arlen W Johnson, Stein Aerts, Jan Cools. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nature Genetics, 2012; DOI: 10.1038/ng.2508

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/~3/t1aTr52MtSw/121223152437.htm

kentucky wildcats oakland school shooting nike nfl jerseys katie couric barista university of kentucky ncaa